Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks.

The outcomes of retreatment patients infected with hepatitis C virus genotype 3, cirrhosis, with velpatasvir may be affected by treatment failure with velpatasvir. The efficacy of SOF+GLE/PIB+RIB 16-24 weeks of treatment has been shown. The presence of NS5A resistance-associated substitution mutations, including Y93H, and the number and regimens of the past failed therapy do not influence the likelihood of achieving sustained virological response.

Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.

The use of direct-acting antiviral agents (DAAs) in patients with chronic HCV genotype (GT) 1 infection results in sustained virologic response (SVR) rates of 95%-97%, but 3%-5% of patients experience virologic failure. We observed 41 patients infected with HCV subtype 1b who failed previous treatment with DAAs, including 37 subjects (90.2%) with liver cirrhosis.

Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin.

The use of direct-acting antiviral agents (DAAs) in patients with chronic HCV genotype 1 infection results in sustained virologic response (SVR) rates of 95%-97%, but 3%-5% of patients experience virologic failure. We observed 17 patients infected with HCV subtype 1b who failed previous treatment with DAA, including 13 subjects (76.5%) with liver cirrhosis.

[Retherapy with lamivudine in hbeag-negative chronic hepatitis B patients unresponsive to interferon/peginterferon treatment].

The paper gives data on retherapy with lamivudine in seven HBeAg-negative chronic hepatitis B patients previously unresponsive to interferon-alpha and peginterferon-alpha2b therapy (6 unresponsive patients and 1 with recurrence). Prior to lamivudine therapy, hepatic biopsy and HBV genotyping were carried out and the baseline level of viremia and the presence of YMDD mutations were determined in all the patients. Its therapeutic efficiency was based on viremia level and AIAT activity at 6, 12, 18, and 24 weeks of treatment.

[Antiphospholipid syndrome at the onset of clinical manifestations of chronic autoimmune hepatitis of type I].

The paper describes a case of chronic autoimmune hepatitis of type I (CAH-I) that showed an onset accompanied by the antiphospholipid syndrome (APS). At the same type, CAH-I ran without both clinical manifestations and the major laboratory syndrome - cytolytic one, which substantially made the diagnosis of a hepatic disease difficult. It is concluded that the clinical manifestations fitting into the APS necessitates meticulous clinical, laboratory, and instrumental studies to find out the underlying disease.